CARA Therapeutics Inc. (CARA)

13.87
NASDAQ : Health Technology
Prev Close 13.87
Day Low/High 0.00 / 0.00
52 Wk Low/High 11.11 / 28.50
Avg Volume 1.04M
Exchange NASDAQ
Shares Outstanding 32.61M
Market Cap 472.16M
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

The Character of the Market Has Shifted

The Character of the Market Has Shifted

The big question right now is to what degree should you be looking to take positions in individual stocks you may like.

8 Stocks That Are Ready to Change Direction

8 Stocks That Are Ready to Change Direction

These names are displaying bullish and bearish reversal patters over the last week.

How Trading Notes Can Increase Your Profits

How Trading Notes Can Increase Your Profits

Inertia is your biggest enemy in this market.

Commit To Buy Cara Therapeutics At $7.50, Earn 12.7% Using Options

Investors eyeing a purchase of Cara Therapeutics Inc shares, but cautious about paying the going market price of $12.46/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2019 put at the $7.50 strike, which has a bid at the time of this writing of 95 cents.

Cara Therapeutics, Thomson Reuters, Wynn Resorts: 'Mad Money' Lightning Round

Cara Therapeutics, Thomson Reuters, Wynn Resorts: 'Mad Money' Lightning Round

Jim Cramer is bullish on Cara Therapeutics, Thomson Reuters, Wynn Resorts, and Edison International.

What's Holding Up This Market?: Cramer's 'Mad Money' Recap (Monday 12/11/17)

What's Holding Up This Market?: Cramer's 'Mad Money' Recap (Monday 12/11/17)

It's just very hard to keep stocks down in this environment, says Jim Cramer. It's part of a synchronized global expansion.

Cara Therapeutics Stock Sees Short Interest Decrease By 13.5%

The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 1,149,738 share decrease in total short interest for Cara Therapeutics Inc , to 7,361,067, a decrease of 13.51% since 10/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Cara Therapeutics Reports Third Quarter 2017 Financial Results

Cara Therapeutics Reports Third Quarter 2017 Financial Results

Management to host conference call today at 4:30 p.m. ET

Cara Therapeutics Doses First Patient In Phase 1 Study Of Oral CR845 In Non-Hemodialysis Chronic Kidney Disease Patients

Cara Therapeutics Doses First Patient In Phase 1 Study Of Oral CR845 In Non-Hemodialysis Chronic Kidney Disease Patients

Study to inform dose selection and design of Phase 2 trial in non-hemodialysis patients with chronic kidney disease-associated pruritus (CKD-aP)

Cara Therapeutics Announces Participation In ANESTHESIOLOGY® 2017

Cara Therapeutics Announces Participation In ANESTHESIOLOGY® 2017

Data from respiratory safety trial of I.V. CR845 to be detailed in oral presentation

Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers

Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers

The South San Francisco, Calif.-based company said Oct. 16 its Phase 3 study of cabozantinib achieved its primary endpoint of overall survival in patients that have advanced hepatocellular carcinoma.

Cara Therapeutics Announces Successful End-of-Phase 2 Meeting With FDA For I.V. CR845 In Chronic Kidney Disease-Associated Pruritus

Cara Therapeutics Announces Successful End-of-Phase 2 Meeting With FDA For I.V. CR845 In Chronic Kidney Disease-Associated Pruritus

Phase 3 pivotal program in hemodialysis patients expected to commence in Q4 2017

Commit To Purchase Cara Therapeutics At $10, Earn 25.1% Annualized Using Options

Investors eyeing a purchase of Cara Therapeutics Inc shares, but tentative about paying the going market price of $13.17/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2018 put at the $10 strike, which has a bid at the time of this writing of $1.50.

Cara Therapeutics (CARA) Shares Cross Above 200 DMA

In trading on Friday, shares of Cara Therapeutics Inc crossed above their 200 day moving average of $14.10, changing hands as high as $16.00 per share. Cara Therapeutics Inc shares are currently trading up about 14.9% on the day.

Cara Therapeutics Reports Second Quarter 2017 Financial Results

Cara Therapeutics Reports Second Quarter 2017 Financial Results

Conference call today at 4:30 p.m. ET

Trump's FDA: A Friendlier Biotech Sheriff

Trump's FDA: A Friendlier Biotech Sheriff

There still will be winners and losers, but the new administration's FDA is a net plus for the industry.

Cara Therapeutics Announces Summary Data From Phase 1 Trial Of Oral CR845 In Hemodialysis Patients With Chronic Kidney Disease

Cara Therapeutics Announces Summary Data From Phase 1 Trial Of Oral CR845 In Hemodialysis Patients With Chronic Kidney Disease

Tablet strengths exhibiting appropriate plasma levels identified for potential use in general CKD-associated pruritus patients